Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Let me save you the trouble Sid and JP: how dare this thieving CEO attend an industry event that cost less than a grand at 5 star Diamond resort...
ya man, like where is Gerald? haven't heard a peep from him in ages. Man, just like that, deadline came and went without ANY WORD WHATSOEVER!!!
you gotta learn to put the past behind you...
I'll let the bottom half of your statement go. more of the same from you. you might be right, but you have no idea.
the top half about CDNF is such a tangled mess of bull. by line:
1. you miss the point
2. you miss the point
3. ya, but for the first time it's in trials
4. sure renishaw has been working on for a long time. but this study is less than a year old, and that proves my point. now is a different time than ever before. The first patient is going to be dosed within the next couple weeks. The main technological barrier to MANF as a medicine is about to be tested for good proof or a huge set back within the next few weeks. The device has safely been implanted. That is a brand new status, brand new evidence, per herantis. This is technological proof in the making. Even though final results for whether CDNF works won't be out for 1.5 years (read the dang site), as long as the study continues, we will know that it's not killing people etc which is good news, we'll know the device is working and CDNF is getting in, which is good news. And you know data and efficacy will leek behind the scenes. As selfish investors, in fact we want CDNF to barely work or barely not work. We want MANF to work.
MANF is essentially in clinical trials right now (CDNF). Big difference now than entire history of company
n2k, I would really like your experienced opinion on one thing in particular.
To me, reading between the lines of the CC, knowing chemistry, and discussing the matter with a pharmacist friend, there is a slim chance FDA allows us to do a bioequivalence bridging study like last year.
What the FDA will require is uncertain, but could be expensive and time demanding because the excipient is a critical component of the product. Elite would be proposing to change a core feature of a product while relying on data gathered on a substantively different product.
If you can give me a simple answer, though one I understand has great complexity to it, what odds do you put on Elite re-submitting the NDA by EOY?
they change a chemical. prior to they were just probably thinning, or changing amounts or something. Nasrat would have put this very predicatble concern, which was asked in a question, to ease if it was same sory as last time. we are very much in doubt now. and if you beleive like I do, that the FDA, while not willing to prevent elite entering the market, is under pressure from big phrma to make the road as difficult as possible, they will find a scientific justification to make elite redo all that.
jesus. all the rest of the pipeline aside, modifying the excipient is going to make almost all the work supporting the original NDA no good. we will probaably be able to pass the nda eventually, but no way FDA accepts the abuse studies etc and the p3 bioequivalence is gonna have to be bigger than if we didn't have to modify
great news on the FDA site visits. hopefully these NDAs come soon
the requirements of what? what are the requirements to talk out of your rear?
for better or worse, I expect the agreement to be different than outlined given the reacquisition of the diagnostics
there has been a lot of dilution since 8-12$, such that an equivalent market cap would be achieved around $0.60
Golden cross. Tomorrow? Wonder if that will attract more buyers or sellers?
Hey Sid, hey JP, and FYI Topknotch.
This company was priced for imminent bankruptcy, firesales etc. That "boy" you dog-whistlers keep yelling about has persisted for all his mistakes, allowing the market to appropriately price the enterprise.
And we have more upside to come. The questions were simple. Did controlling parties stand to be richer with AMBS failure or succcess? Did GC have the heart to continue?
You all let past bias get in the way of sound analysis. I thought we were"exhausted" "over-extended" No, the rally goes on. Will people who only bought a pre-rev bio pre R/S ever get their money back? Probably not. But that's so common. What's uncommon is vested, gritty management. What's uncommon an extraordinary asset and decent pipeline. You failed to see it, and until you do, you will be mad and in the hole.
I'm invested for free right now due to the recent run. You're still mad about stuff that happened years ago, you're still mad at others without taking any personal responsibility. You get what you deserve.
the float does not need to churn bigley, several times over lol laughable. Explain yourself. If I really want to buy 1 share and no one will sell for under $5, the market price will become $5 when I pay it.
I'm not saying we don't see corrections on the way up, but all is well until the fat lady sings. No reason to believe things can't get extended past jan 10 anyway.
Oct 2012. AMBS is less than $1, split adjusted. By beginning 2013, it was 20x higher. So for us that's around 0.40?
0.01 looked less crazy than .10 2 weeks ago, right JP?
Could it possibly be, that organic interest will accelerate the price climb as fewer and fewer nervous hands, traders, and disciplined investors who can smell a bluff stop selling into the buying?
How many of those 120M shares are held by people who bought at .10, at .20, at .40, .80, 1.60, 3.20 etc?
It's not crazy to rise almost as fast as we fell. We were 7.50 at the R/S. Now we have 12x shares. Why isn't 60 cents reasonable? Why isn't he $4.66 200wma reasonable? If certain entities acquired all these excess shares after shorting and control all the volume, what do they want for the shares? I'm not sure, are you? The only thing I've been sure and remain sure about is everyone is richer if this company survives.
thanks zoom. JP, waiting for you to try and ruin my day. Congrats all.
.02365 eod
no, the giant bids and asks. You're quoting a guy who is reporting what he saw on a single brokerage which has a history of glitchy bid ask reporting.
and as for the trips, again, $2000 hysterical sell out led to .01 and maybe your unprinted trips. No one cares about that. Somebody jacked this thing to .05 on nothing a few weeks ago. This thing can make moves easy. that's all it proves.
dude, #1 no one else saw those numbers on their brokerages
#2 that's balogney and he's reported weird bid/ask in millions before. still no trips
#3 show some proof or shut up
#4 can't disagree with me today, it's veteran's day
Are you kidding me? I want to be here when those 0.001's you keep telling
us about come.
Premarket it not showing .001's, you're lying and premarket is irrelevant anyway. I am not at all concerned by a reactionary sell-off of $2000 worth of shares at the open.
I am concerned by our situation in general but that list stands tall.
1. get real
2. buck institute begs to differ. demonstratively helpful to stem cell therapies
3.Fumi Urano begs to differ. Human trial by 2020
4.Funding is dire and critical
5. Maybe he will. He's staying on the field
6. AMBS is owned by its shareholders. Not CHF. Spreading FUD and nonsense
7. I'm hip old man, don't you worry
MANF is a protein in a box
nothing more - nothing less
it is being surpassed by stem cell advances left and right
it is at least 5 - 7 years away from any conceivable human trials whatsoever
and of course, funding appears to be the most dire and critical need - as usual
who knows, maybe Gerald will sell his $130k Tesla and throw those coins in the MANF development bucket
instead of continually sucking AMBS dry
and royally screwing his few remaining loyal shareholders
with lavish travel, high fluting dining, and an unlimited expense account
Oh wiat - that's right
Gerald sold AMBS for $25k to Chang of SeD
so he could now fleece AVDX shareholders
get hip - or get swindled...Brah
penicillin was discovered in 1928. Not introduced until the 1940s. The list is long, your logic is short.
and 123 shares to end the day. lol toy trades
someone, or something, sold 234 shares at .0275
the end is nigh!!! lol
?joboggi, who are you talking to and what about?
I see 200,000 buys above .03, but that's just me...
how many times must I insist, please don't cross post my posts.
and BK is just shorthand for a number of negative outcomes. I did not specify anything
A more realistic scenario is the DGF told GC they needed the convertible language for downside protection, and would be happy to add in the NASDAQ language for AMBS upside benefit, and Gerald took their word for it on a handshake and they boned us. Foolish, naive. No evidence of corruption. At that point, Gerald had to take on literally anybody to get out of Discover, and Magna's prior relationship with him was best option. But we'll never know, win or lose.
JP, 10x is predicated on a deal as priorly outlined that removes the weight of default, and therefore removes the immediate default pricing. Evidence continues to mount that a deal will be made. Terms will dictate the upside, but there will be significant upside typical for an extremely oversold company, many of whom's holders have way, way, way higher average buy prices.
Updates coming in "near future."
someone is going to have to sell over 300k shares first
ya so true Zoom. paint up is a hundred or 1000 shares. paint down is a homeless guy at the library selling for a McDouble on his way home to the overpass...
JP, another thing I'd like to point out is, if SeD Biomedical, who's stated purpose is to assist in the funding and restructuring of biotechnology companies, is committed to an Amarantus turnaround, that is a big impediment to Magna et al collecting through the BK, carve up scenario you describe. In normal circumstances, shareholders always try to oppose being cut out. It's simply almost always to difficult to band together enough parties with the money and will to effectively challenge the claims of creditors. SeD has the resources, and might have the will to draw out such a circumstance, costing Magna et al significant costs.
You continue to mention that AMBS has to come up with 16-17M dollars. They certainly do not, the LOI speaks to this fact, that on principle, parties agreed to take over certain AMBS assets in exchange for clearing the books. No doubt, AMBS has accumulated several millions in payables, and needs funding after that, but with a clear cap structure and all the scientific progress on MANF, elto, and administration, this is not nearly as difficult to imagine as it was when AMBS was forced, or dummied into the toxics 2 years ago. Future is bright man, much brighter that a year ago.
I described a realistic and moderately conservative scenario on the other board where we walk out of here with effectively $0.25-0.40 shares and a solid foundation for growth. Many unknowns remain. But this is gonna happen, just like CHF turned SeD around, he is going to turn Amarantus around and share in our success. He's not Warren Buffett. But then again, we're not Bank of America. He's a well-resourced, well-intentioned man who has declared his will.
even without the paint it finishes above .04
well, marcum is bigger than just CPAs, and CPAs see the books. Just a thought.
perhaps they were also corrupt...
JP, what did you think of Avant dropping Marcum for Weinstein?
JP, none of what you mentioned is mutually exclusive to a turnaround. The list of pre-rev biotechs that have huge valuations or medium sized valuations, or tiny valuations is long. Almostt as long as the list of pre-rev bios that die.
We are priced for bankruptcy right now. There are many paths ahead that avoid bankruptcy that create "shareholder value" as the ole boy says simply because market prices us dead. Market has forgotten us.
I cannot tell you how we'll produce revenue because we probably won't (although share sales of AVDX may become revenue depending on the deal.) And I think, as long as you've been here, if you've avoided averaging down, you will never make your money back, which is why I don't understand why you're here, but bless your heart. I'm saying you can dish a little cash here with good risk reward based on how volatile the price is and the improving circumstances. Your concerns for the company's circumstances are obvious, but there is clearly a willingness by all parties to let the company right itself outside the courts, probably because it makes the most money sense to all parties. $ talks, and turnaround is only good option.
I literally gave you a list. We're not reading tea leaves here. The circumstances around the company are obviously suggesting turnaround support. To what end I don't know. they will def have to raise at some point, but a deal, as from the LOI was literally written for you to read that gets them out of immediate danger and it's looking like it's gonna happen, not looking like it's not gonna happen.
JP, honestly man, I know you've been burned, but you've got an opportunity to make yourself whole or better here. Mcap is <5mil right now. If we're not destitute that's crazy low...
FOR:
still no default filings
still no call on loans
All parties verify working things out
SeD working through auditor selection, yet no EGM announced
SeD clearly going all in on BioMed with Dr. Tang
proposed asset infusion under new collaboration
Dr. Urano plainly getting attention and big dollars
MANF research continues to pour out
Herantis still hasn't launch CDNF trial
Herantis clearly interested in MANF
Gene therapy clearly becoming a successful route
Infusion 51a sitting on cash
AVDX set to turn around with $ and Dr. Goix
AGAINST:
JP
JP, are you getting nervous? Are you sure Spence said what he said? Because I see a big open above averages, outside the triangle? with a sitting bid not seen in months...